このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (onset 9)

2022年1月6日 更新者：Novo Nordisk A/S

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)

The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).

調査の概要

状態

状態

現在の募集状況やアクセス拡大状況を示します。
完了

条件

条件

研究されている疾患、障害、症候群、病気、またはけが。 ClinicalTrials.gov では、条件には、寿命、生活の質、健康上のリスクなど、他の健康関連の問題も含まれる場合があります。

介入・治療

介入・治療

臨床研究の焦点となるプロセスまたはアクション。介入には、医薬品、医療機器、処置、ワクチン、および治験中またはすでに利用可能なその他の製品が含まれます。介入には、教育や食事や運動の変更などの非侵襲的アプローチも含まれます。

研究の種類

研究の種類

臨床研究の性質について説明します。研究の種類には、介入研究 (臨床試験とも呼ばれます)、観察研究 (患者登録を含む)、および拡張アクセスが含まれます。
介入

入学 (実際)

入学

臨床試験の参加者数。 「予想される」登録は、研究者が研究に必要とする参加者の目標数です。
1264

段階

段階

米国食品医薬品局 (FDA) によって開発された定義に基づく、医薬品または生物学的製品を研究する臨床試験の段階。フェーズは、研究の目的、参加者の数、およびその他の特性に基づいています。初期フェーズ 1 (以前はフェーズ 0 としてリストされていた)、フェーズ 1、フェーズ 2、フェーズ 3、およびフェーズ 4 の 5 つのフェーズがあります。該当なしは、デバイスまたは行動介入の治験を含む、FDA が定義したフェーズのない治験を説明するために使用されます。
  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • アメリカ
    • California
      • Concord、California、アメリカ、94520
        • Novo Nordisk Investigational Site
      • Fresno、California、アメリカ、93720
        • Novo Nordisk Investigational Site
      • Fullerton、California、アメリカ、92835
        • Novo Nordisk Investigational Site
      • Lancaster、California、アメリカ、93534
        • Novo Nordisk Investigational Site
      • Norco、California、アメリカ、92860
        • Novo Nordisk Investigational Site
      • Sacramento、California、アメリカ、95821
        • Novo Nordisk Investigational Site
      • Ventura、California、アメリカ、93003
        • Novo Nordisk Investigational Site
      • Walnut Creek、California、アメリカ、94598
        • Novo Nordisk Investigational Site
    • Colorado
      • Denver、Colorado、アメリカ、80246
        • Novo Nordisk Investigational Site
      • Golden、Colorado、アメリカ、80401
        • Novo Nordisk Investigational Site
    • Connecticut
      • Waterbury、Connecticut、アメリカ、06708
        • Novo Nordisk Investigational Site
    • Florida
      • Boynton Beach、Florida、アメリカ、33472
        • Novo Nordisk Investigational Site
      • Bradenton、Florida、アメリカ、34201
        • Novo Nordisk Investigational Site
      • Fort Lauderdale、Florida、アメリカ、33312
        • Novo Nordisk Investigational Site
      • Miami、Florida、アメリカ、33174
        • Novo Nordisk Investigational Site
      • Tampa、Florida、アメリカ、33634
        • Novo Nordisk Investigational Site
    • Georgia
      • Alpharetta、Georgia、アメリカ、30022
        • Novo Nordisk Investigational Site
      • Lawrenceville、Georgia、アメリカ、30046
        • Novo Nordisk Investigational Site
      • Roswell、Georgia、アメリカ、30076
        • Novo Nordisk Investigational Site
    • Hawaii
      • Honolulu、Hawaii、アメリカ、96814
        • Novo Nordisk Investigational Site
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • Novo Nordisk Investigational Site
      • Peoria、Illinois、アメリカ、61603
        • Novo Nordisk Investigational Site
      • Springfield、Illinois、アメリカ、62711
        • Novo Nordisk Investigational Site
    • Indiana
      • Valparaiso、Indiana、アメリカ、46383
        • Novo Nordisk Investigational Site
    • Iowa
      • West Des Moines、Iowa、アメリカ、50266
        • Novo Nordisk Investigational Site
    • Kansas
      • Topeka、Kansas、アメリカ、66606
        • Novo Nordisk Investigational Site
    • Kentucky
      • Lexington、Kentucky、アメリカ、40503
        • Novo Nordisk Investigational Site
      • Lexington、Kentucky、アメリカ、40502
        • Novo Nordisk Investigational Site
    • Maryland
      • Rockville、Maryland、アメリカ、20852
        • Novo Nordisk Investigational Site
    • Massachusetts
      • Waltham、Massachusetts、アメリカ、02453
        • Novo Nordisk Investigational Site
      • Worcester、Massachusetts、アメリカ、01655
        • Novo Nordisk Investigational Site
    • Nevada
      • Henderson、Nevada、アメリカ、89052-2649
        • Novo Nordisk Investigational Site
      • Las Vegas、Nevada、アメリカ、89148
        • Novo Nordisk Investigational Site
    • New Hampshire
      • Nashua、New Hampshire、アメリカ、03063
        • Novo Nordisk Investigational Site
    • New York
      • Northport、New York、アメリカ、11768
        • Novo Nordisk Investigational Site
      • West Seneca、New York、アメリカ、14224
        • Novo Nordisk Investigational Site
    • North Carolina
      • Asheville、North Carolina、アメリカ、28803
        • Novo Nordisk Investigational Site
      • Chapel Hill、North Carolina、アメリカ、27514
        • Novo Nordisk Investigational Site
    • Ohio
      • Mentor、Ohio、アメリカ、44060
        • Novo Nordisk Investigational Site
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73104-5020
        • Novo Nordisk Investigational Site
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19140
        • Novo Nordisk Investigational Site
    • South Carolina
      • Greenville、South Carolina、アメリカ、29605-4254
        • Novo Nordisk Investigational Site
    • Tennessee
      • Chattanooga、Tennessee、アメリカ、37404
        • Novo Nordisk Investigational Site
      • Chattanooga、Tennessee、アメリカ、37411
        • Novo Nordisk Investigational Site
      • Nashville、Tennessee、アメリカ、37212
        • Novo Nordisk Investigational Site
    • Texas
      • Amarillo、Texas、アメリカ、79106
        • Novo Nordisk Investigational Site
      • Austin、Texas、アメリカ、78731
        • Novo Nordisk Investigational Site
      • Austin、Texas、アメリカ、78749
        • Novo Nordisk Investigational Site
      • Beaumont、Texas、アメリカ、77701
        • Novo Nordisk Investigational Site
      • Dallas、Texas、アメリカ、75230
        • Novo Nordisk Investigational Site
      • Dallas、Texas、アメリカ、75226
        • Novo Nordisk Investigational Site
      • Dallas、Texas、アメリカ、75231
        • Novo Nordisk Investigational Site
      • Longview、Texas、アメリカ、75605
        • Novo Nordisk Investigational Site
      • Pearland、Texas、アメリカ、77584
        • Novo Nordisk Investigational Site
      • Round Rock、Texas、アメリカ、78681
        • Novo Nordisk Investigational Site
    • Utah
      • Ogden、Utah、アメリカ、84405
        • Novo Nordisk Investigational Site
    • Vermont
      • Bennington、Vermont、アメリカ、05201
        • Novo Nordisk Investigational Site
      • South Burlington、Vermont、アメリカ、05403
        • Novo Nordisk Investigational Site
    • Virginia
      • Chesapeake、Virginia、アメリカ、23321
        • Novo Nordisk Investigational Site
      • Winchester、Virginia、アメリカ、22601-3834
        • Novo Nordisk Investigational Site
    • Washington
      • Olympia、Washington、アメリカ、98502
        • Novo Nordisk Investigational Site
      • Seattle、Washington、アメリカ、98105
        • Novo Nordisk Investigational Site
      • Spokane、Washington、アメリカ、99201
        • Novo Nordisk Investigational Site
    • Wisconsin
      • Green Bay、Wisconsin、アメリカ、54303
        • Novo Nordisk Investigational Site
  • アルゼンチン
      • Caba、アルゼンチン、C1060ABA
        • Novo Nordisk Investigational Site
      • Caba、アルゼンチン、C1440AAD
        • Novo Nordisk Investigational Site
      • Cordoba、アルゼンチン、5000
        • Novo Nordisk Investigational Site
      • Córdoba、アルゼンチン、5008
        • Novo Nordisk Investigational Site
  • イタリア
      • Catanzaro、イタリア、88100
        • Novo Nordisk Investigational Site
      • Chieti、イタリア、66100
        • Novo Nordisk Investigational Site
      • Cittadella (PD)、イタリア、35013
        • Novo Nordisk Investigational Site
      • Milano (MI)、イタリア、20132
        • Novo Nordisk Investigational Site
      • Olbia、イタリア、07026
        • Novo Nordisk Investigational Site
      • Palermo、イタリア、90129
        • Novo Nordisk Investigational Site
  • ウクライナ
      • Dnipro、ウクライナ、49038
        • Novo Nordisk Investigational Site
      • Kharkiv、ウクライナ、61000
        • Novo Nordisk Investigational Site
      • Kyiv、ウクライナ、03049
        • Novo Nordisk Investigational Site
      • Lviv、ウクライナ、79010
        • Novo Nordisk Investigational Site
      • Ternopil、ウクライナ、46002
        • Novo Nordisk Investigational Site
      • Vinnytsia、ウクライナ、21010
        • Novo Nordisk Investigational Site
  • カナダ
    • Alberta
      • Edmonton、Alberta、カナダ、T6G 2E1
        • Novo Nordisk Investigational Site
    • British Columbia
      • Victoria、British Columbia、カナダ、V8V 4A1
        • Novo Nordisk Investigational Site
    • Nova Scotia
      • Halifax、Nova Scotia、カナダ、B3H 2Y9
        • Novo Nordisk Investigational Site
    • Ontario
      • Barrie、Ontario、カナダ、L4N 7L3
        • Novo Nordisk Investigational Site
      • Concord、Ontario、カナダ、L4K 4M2
        • Novo Nordisk Investigational Site
      • Etobicoke、Ontario、カナダ、M9R 4E1
        • Novo Nordisk Investigational Site
      • Hamilton、Ontario、カナダ、L8M 1K7
        • Novo Nordisk Investigational Site
      • Newmarket、Ontario、カナダ、L3Y 5G8
        • Novo Nordisk Investigational Site
      • Thunder Bay、Ontario、カナダ、P7A 4V7
        • Novo Nordisk Investigational Site
      • Toronto、Ontario、カナダ、M4G 3E8
        • Novo Nordisk Investigational Site
    • Quebec
      • Montreal、Quebec、カナダ、H4T 1Z9
        • Novo Nordisk Investigational Site
  • ギリシャ
      • Athens、ギリシャ、GR-11527
        • Novo Nordisk Investigational Site
      • Athens、ギリシャ、115 25
        • Novo Nordisk Investigational Site
      • Ioannina、ギリシャ、45500
        • Novo Nordisk Investigational Site
      • Larissa、ギリシャ、GR-41110
        • Novo Nordisk Investigational Site
      • Thessaloniki、ギリシャ、GR-54636
        • Novo Nordisk Investigational Site
      • Thessaloniki、ギリシャ、GR-57001
        • Novo Nordisk Investigational Site
      • Thessaloniki、ギリシャ、GR-54642
        • Novo Nordisk Investigational Site
      • Thessaloniki、ギリシャ、GR-54643
        • Novo Nordisk Investigational Site
  • クロアチア
      • Karlovac、クロアチア、47000
        • Novo Nordisk Investigational Site
      • Osijek、クロアチア、31 000
        • Novo Nordisk Investigational Site
      • Varazdin、クロアチア、42 000
        • Novo Nordisk Investigational Site
      • Zagreb、クロアチア、10 000
        • Novo Nordisk Investigational Site
  • スペイン
      • Alcobendas、スペイン、28100
        • Novo Nordisk Investigational Site
      • Almería、スペイン、04001
        • Novo Nordisk Investigational Site
      • Girona、スペイン、17007
        • Novo Nordisk Investigational Site
      • La Coruña、スペイン、15006
        • Novo Nordisk Investigational Site
      • Pozuelo de Alarcon、スペイン、28223
        • Novo Nordisk Investigational Site
      • Sabadell、スペイン、08208
        • Novo Nordisk Investigational Site
      • Sevilla、スペイン、41010
        • Novo Nordisk Investigational Site
      • Sevilla、スペイン、41003
        • Novo Nordisk Investigational Site
  • スロバキア
      • Kosice、スロバキア、040 01
        • Novo Nordisk Investigational Site
      • Kysucke Nove Mesto、スロバキア、024 01
        • Novo Nordisk Investigational Site
      • Lubochna、スロバキア、03491
        • Novo Nordisk Investigational Site
      • Lucenec、スロバキア、984 01
        • Novo Nordisk Investigational Site
      • Zilina、スロバキア、01001
        • Novo Nordisk Investigational Site
  • セルビア
      • Belgrade、セルビア、11000
        • Novo Nordisk Investigational Site
      • Kragujevac、セルビア、34000
        • Novo Nordisk Investigational Site
      • Nis、セルビア、18000
        • Novo Nordisk Investigational Site
      • Novi Sad、セルビア、21000
        • Novo Nordisk Investigational Site
      • Zajecar、セルビア、19000
        • Novo Nordisk Investigational Site
  • チェコ
      • Hradec Kralove、チェコ、500 05
        • Novo Nordisk Investigational Site
      • Plzen、チェコ、30100
        • Novo Nordisk Investigational Site
      • Plzen、チェコ、32600
        • Novo Nordisk Investigational Site
      • Trutnov、チェコ、541 01
        • Novo Nordisk Investigational Site
  • ドイツ
      • Dresden、ドイツ、01219
        • Novo Nordisk Investigational Site
      • Essen、ドイツ、45136
        • Novo Nordisk Investigational Site
      • Falkensee、ドイツ、14612
        • Novo Nordisk Investigational Site
      • Lingen、ドイツ、49808
        • Novo Nordisk Investigational Site
      • Münster、ドイツ、48145
        • Novo Nordisk Investigational Site
      • Saint Ingbert-Oberwürzbach、ドイツ、66386
        • Novo Nordisk Investigational Site
      • Schweinfurt、ドイツ、97421
        • Novo Nordisk Investigational Site
  • ブルガリア
      • Kozloduy、ブルガリア、3320
        • Novo Nordisk Investigational Site
      • Razgrad、ブルガリア、7200
        • Novo Nordisk Investigational Site
      • Sofia、ブルガリア、1233
        • Novo Nordisk Investigational Site
      • Sofia、ブルガリア、1618
        • Novo Nordisk Investigational Site
  • プエルトリコ
      • Ponce、プエルトリコ、00716
        • Novo Nordisk Investigational Site
  • ポーランド
      • Bialystok、ポーランド、15-435
        • Novo Nordisk Investigational Site
      • Skorzewo、ポーランド、60-185
        • Novo Nordisk Investigational Site
      • Warsaw、ポーランド、00-465
        • Novo Nordisk Investigational Site
      • Warsaw、ポーランド、02-793
        • Novo Nordisk Investigational Site
      • Warszawa、ポーランド、02-507
        • Novo Nordisk Investigational Site
      • Wroclaw、ポーランド、50-381
        • Novo Nordisk Investigational Site
  • ルーマニア
      • Brasov、ルーマニア、500101
        • Novo Nordisk Investigational Site
      • Brasov、ルーマニア、500283
        • Novo Nordisk Investigational Site
      • Bucharest、ルーマニア、13682
        • Novo Nordisk Investigational Site
    • Maramures
      • Baia Mare、Maramures、ルーマニア、430222
        • Novo Nordisk Investigational Site
    • Mures
      • Tirgu Mures、Mures、ルーマニア、540142
        • Novo Nordisk Investigational Site
    • Timis
      • Timisoara、Timis、ルーマニア、300125
        • Novo Nordisk Investigational Site
  • ロシア連邦
      • Arkhangelsk、ロシア連邦、163045
        • Novo Nordisk Investigational Site
      • Kazan、ロシア連邦、420073
        • Novo Nordisk Investigational Site
      • Moscow、ロシア連邦、123448
        • Novo Nordisk Investigational Site
      • Penza、ロシア連邦、440026
        • Novo Nordisk Investigational Site
      • Saint Petersburg、ロシア連邦、194291
        • Novo Nordisk Investigational Site
      • Saint-Petersburg、ロシア連邦、194356
        • Novo Nordisk Investigational Site
      • Tumen、ロシア連邦、625023
        • Novo Nordisk Investigational Site
      • Voronezh、ロシア連邦、394018
        • Novo Nordisk Investigational Site
  • 大韓民国
      • Bucheon、大韓民国、14647
        • Novo Nordisk Investigational Site
      • Daegu、大韓民国、42472
        • Novo Nordisk Investigational Site
      • Seongnam-si、大韓民国、463-707
        • Novo Nordisk Investigational Site
      • Seoul、大韓民国、02447
        • Novo Nordisk Investigational Site
      • Seoul、大韓民国、03080
        • Novo Nordisk Investigational Site
      • Seoul、大韓民国、04516
        • Novo Nordisk Investigational Site
      • Seoul、大韓民国、06351
        • Novo Nordisk Investigational Site
      • Seoul、大韓民国、08308
        • Novo Nordisk Investigational Site
      • Seoul、大韓民国、137-701
        • Novo Nordisk Investigational Site
      • Wonju、大韓民国、26426
        • Novo Nordisk Investigational Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

適格基準

臨床研究への参加を希望する人々が満たさなければならない重要な要件、または彼らが持つべき特徴。適格基準は、包含基準 (人が研究に参加するために必要な基準) と除外基準 (人が研究に参加するのを妨げる基準) の両方で構成されます。適格基準のタイプには、研究が健康なボランティアを受け入れるかどうか、年齢または年齢グループの要件があるかどうか、または性別によって制限されるかどうかが含まれます。

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria: - Male or female, age equal to or above 18 years at the time of signing informed consent. - Diagnosed with type 2 diabetes mellitus for 10 years or longer prior to screening (Visit 1). - Treated with a basal-bolus insulin regimen for 1 year or longer prior to the day of screening (Visit 1). A basal-bolus insulin regimen is defined as basal insulin once or twice daily and bolus insulin analogue taken with meals at least 3 times daily. Treatment with premixed insulin or soluble insulin combination is not considered a basal-bolus regimen. - Treated with or without oral antidiabetic drugs including extended release formulations. - HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory at screening (Visit 1). Exclusion Criteria: - Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening (Visit 1). - Subjects presently classified as being in New York Heart Association (NYHA) Class IV. - Planned coronary, carotid or peripheral artery revascularisation known on the day of screening (Visit 1). - Treatment with injectable GLP-1 receptor agonists in a period of 90 days prior to screening (Visit 1). - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or corticosteroids).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：4倍

武器と介入

参加者グループ / アーム

参加者グループ / アーム

臨床試験のプロトコルに従って、特定の介入/治療を受ける、または介入を受けない、臨床試験の参加者のグループまたはサブグループ。
介入・治療

介入・治療

臨床研究の焦点となるプロセスまたはアクション。介入には、医薬品、医療機器、処置、ワクチン、および治験中またはすでに利用可能なその他の製品が含まれます。介入には、教育や食事や運動の変更などの非侵襲的アプローチも含まれます。
実験的：Faster aspart + insulin degludec with or without metformin
薬：Faster-acting insulin aspart
Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
薬：Insulin degludec
Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
薬：Metformin
Only participants who took metformin before the study should take metformin tablets, same dose as before the study
アクティブコンパレータ：NovoRapid/NovoLog + insulin degludec with or without metformin
薬：Insulin degludec
Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
薬：Metformin
Only participants who took metformin before the study should take metformin tablets, same dose as before the study
薬：Insulin aspart
Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.

この研究は何を測定していますか？

主要な結果の測定

主要な結果の測定

臨床研究のプロトコルにおいて、介入/治療の効果を評価するために最も重要な、計画された結果の尺度。ほとんどの臨床研究には 1 つの主要な結果の測定値がありますが、複数の測定値を持つものもあります。
結果測定
メジャーの説明
時間枠
Change in Glycosylated Haemoglobin (HbA1c)
時間枠：Week 0, week 16
Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 16. The endpoint was evaluated based on data from the in-trial observation period. In-trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16

二次結果の測定

二次結果の測定

臨床研究のプロトコルにおいて、介入の効果を評価するための主要な結果測定ほど重要ではないが、依然として重要な計画された結果測定。ほとんどの臨床研究には、複数の副次的アウトカム指標があります。
結果測定
メジャーの説明
時間枠
Change From Baseline in 1-hour PPG Increment
時間枠：Week 0, week 16
Change from baseline (week 0) in 1-hour postprandial glucose (PPG) increment was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline in 1,5-anhydroglucitol
時間枠：Week 0, week 16
Change from baseline (week 0) in 1,5-anhydroglucitol was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline in Fasting Plasma Glucose (FPG)
時間枠：Week 0, week 16
Change from baseline (week 0) in fasting plasma glucose was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Participants Who Achieved HbA1c <7.0% (53 mmol/L) (Yes/No)
時間枠：16 weeks after randomisation
Number of participants reaching HbA1c <7.0% (53 mmol/L) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Participants Who Achieved HbA1c <7.0% (53 mmol/L) Without Severe Hypoglycaemia Episodes (Yes/No)
時間枠：16 weeks after randomisation
Number of participants reaching HbA1c <7.0% (53 mmol/L) without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour Postprandial Glucose (PPG [Meal Test])
時間枠：Week 0, week 16
Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour postprandial glucose (PPG [meal test]) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal.
Week 0, week 16
Change From Baseline (Week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG Increment (Meal Test)
時間枠：Week 0, week 16
Change from baseline (week 0) in 30-minute, 1-hour, 2-hour, 3-hour and 4-hour PPG increment (meal test) was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact. Meal test: The subjects were given a carbohydrate-rich standardised liquid meal immediately after bolus (faster aspart or NovoRapid) infusion in the morning of the meal test. The subjects were to consume the meal as quickly as possible (within 12 minutes) and blood samples were drawn after 30 minutes, 1, 2, 3 and 4 hours from the start of the meal. PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value.
Week 0, week 16
Change From Baseline in Mean of the 7-9-7 Point Self-measured Plasma Glucose (SMPG) Profile
時間枠：Week 0, week 16
Change from baseline (week 0) in mean of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. 7-9-7 point SMPG was measured at the following mentioned time points: 1) Before breakfast, 2) 60 mins after the start of Breakfast, 3) Before lunch, 4) 60 mins after the start of lunch, 5) Before main evening meal, 6) 60 mins after the start of main evening meal, 7) At bedtime, 8) At 4 AM, 9) Before breakfast.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: PPG (Mean, Breakfast, Lunch and Main Evening Meal)
時間枠：Week 0, week 16
Change from baseline (week 0) in PPG (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: PPG Increment (Mean, Breakfast, Lunch and Main Evening Meal)
時間枠：Week 0, week 16
Change from baseline (week 0) in PPG increment (breakfast, lunch, main evening meal and mean over all meals) of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. PPG increment based on the 7-9-7-point profiles were derived separately for PG measurements made at 1 hour after main meals (breakfast, lunch and main evening meal). PPG incremental value for each time point was derived as PPG value at that time point minus the preprandial glucose value. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: Fluctuation in 7-9-7 Point Profile
時間枠：Week 0, week 16
Fluctuation in 7-point SMPG profile was the average absolute difference from the mean of the SMPG profile. Reported results are fluctuation in the 7-9-7 point SMPG profile from baseline (week 0) after 16 weeks of randomisation (i.e., week 16). The results are presented as ratio to baseline. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Change From Baseline of the 7-9-7 Point SMPG Profile: Nocturnal SMPG Measurements
時間枠：Week 0, week 16
Change from baseline (week 0) in nocturnal SMPG measurements was assessed by considering the differences between PG values available at bedtime, at 4 AM and the before breakfast value the following day: (4 AM PG value minus at bedtime PG value), (before breakfast PG value minus at bedtime PG value) and (before breakfast PG value minus 4 AM PG value). Change from baseline in nocturnal increments in SMPG measurements of the 7-9-7 point SMPG profile was evaluated after 16 weeks of randomisation and presented during three different time intervals as follows: 1) 04:00 to breakfast, 2) bedtime to 04:00, and 3) bedtime to breakfast. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Participants Who Achieved Overall PPG (1 Hour) <7.8 mmol/L (140 mg/dL) (Yes/No)
時間枠：16 weeks after randomisation
Participants reaching overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Participants Who Achieved Overall PPG <7.8 mmol/L (140 mg/dL) Without Severe Hypoglycaemia Episodes (Yes/No)
時間枠：16 weeks after randomisation
Participants reaching overall PPG (1 hour) ≤7.8 mmol/L [140 mg/dL] without severe hypoglycaemia episodes was evaluated after 16 weeks of randomisation. Participants without a postprandial glucose measurement at week 16 were considered not to have achieved HbA1c target at week 16. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
16 weeks after randomisation
Total Bolus Insulin Dose: in Units/Day
時間枠：16 weeks from randomisation
Total bolus insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Bolus Insulin Dose: in Units/kg/Day
時間枠：16 weeks from randomisation
Total bolus insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Basal Insulin Dose: in Units/Day
時間枠：16 weeks from randomisation
Total basal insulin dose (Units/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Total Basal Insulin Dose: in Units/kg/Day
時間枠：16 weeks from randomisation
Total basal insulin dose (Units/kg/day) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Individual Meal Insulin Dose: in Units
時間枠：16 weeks from randomisation
Individual meal time bolus insulin dose (Units) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Individual Meal Insulin Dose: in Units/kg
時間枠：16 weeks from randomisation
Individual meal time bolus insulin dose (Units/kg) for breakast, lunch and main evening meal was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
16 weeks from randomisation
Change From Baseline in Lipids-lipoproteins Profile (Total Cholesterol, High Density Lipoproteins, Low Density Lipoproteins) - Ratio to Baseline
時間枠：Week 0, week 16
Reported results are lipids-lipoproteins (total cholesterol, high density lipoproteins, low density lipoproteins) values are given as ratio to baseline (week 0) after 16 weeks. The results are based on the last in-trial value, which included the last available measurement in the in-trial period. In trial observation period was from date of randomisation and until last trial-related participant-site contact.
Week 0, week 16
Number of Treatment Emergent Adverse Events
時間枠：Weeks 0-16
Number of treatment emergent adverse events were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Injection Site Reactions
時間枠：Weeks 0-16
Number of treatment emergent injection site reactions were recorded from week 0 to week 16. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes (Hypos) According to the American Diabetes Association (ADA) and Novo Nordisk (NN) Definition: Overall
時間枠：Weeks 0-16

ADA classification of hypos:

  1. Severe: Requiring assistance of another person to actively administer carbohydrate/glucagon/take other corrective actions. PG levels may not be available during an event, but neurological recovery following return of PG to normal is considered sufficient evidence that event was induced by a low PG level.
  2. Documented symptomatic: PG ≤3.9 mmol/L with symptoms.
  3. Asymptomatic: PG ≤3.9 mmol/L without symptoms.
  4. Probable symptomatic: No measurement with symptoms.
  5. Pseudo: PG >3.9 mmol/L with symptoms.
  6. Unclassifiable.

NN classification of hypos:

  1. BG confirmed: PG <3.1 mmol/L with/without symptoms.
  2. Severe or BG confirmed symptomatic: Severe as per ADA and BG confirmed by PG <3.1 mmol/L with symptoms.
  3. Severe or BG confirmed: Severe as per ADA and BG confirmed by PG <3.1 mmol/L with/without symptoms.
  4. Unclassifiable. Not able to self treat-unclassifiable: Not able to self treat but not classifiable as severe hypoglycaemia.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Daytime Hypoglycaemic Episodes (06:00-00:00 - Inclusive)
時間枠：Weeks 0-16
Number of treatment emergent day time hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 06:00 and 00:00 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Nocturnal Hypoglycaemic Episodes (00:01-05:59 - Inclusive)
時間枠：Weeks 0-16
Number of treatment emergent nocturnal hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 00:01 and 05:59 (both included). The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 1 Hour After Start of the Meal
時間枠：Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 1 hour after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 2 Hours After Start of the Meal
時間枠：Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 2 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and Novo Nordisk Definition: Hypoglycaemic Episodes During First 4 Hours After Start of the Meal
時間枠：Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated during the first 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Number of Treatment Emergent Hypoglycaemic Episodes According to the American Diabetes Association and NN Definition: Hypoglycaemic Episodes Occurring Between 2 to 4 Hours After Start of the Meal
時間枠：Weeks 0-16
Number of treatment emergent hypoglycaemic episodes according to the ADA and NN definitions were evaluated between 2 to 4 hours after start of the meal. The results are based on the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Weeks 0-16
Change From Baseline in Physical Examination
時間枠：Week 0, week 16
Participants with physical examination findings, normal, abnormal NCS (non- clinically significant) and abnormal CS (clinically significant) at baseline (week 0) and week 16 presented. Results are based on the data from the on-treatment observation period, which was the time period from when a participant was randomised until the final scheduled visit, including any period after initiation of rescue medication and/or premature discontinuation of trial product. Results are presented for the following examinations: 1) Cardiovascular system 2) Central & Peripheral nervous system 3) Gastrointestinal system incl. mouth 4) Head, ears, eyes, nose, throat and neck 5) Musculoskeletal system 6) Respiratory system 7) Skin
Week 0, week 16
Change From Baseline in Vital Signs: Systolic and Diastolic Blood Presure
時間枠：Week 0, week 16
Change in vital signs - systolic and diastolic blood pressure from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Vital Signs: Pulse
時間枠：Week 0, week 16
Change in vital signs - pulse from baseline (week 0) was evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Electrocardiogram (ECG)
時間枠：Week 0, week 16
Changes in electrocardiogram (ECG) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Fundoscopy/Fundus Photography
時間枠：Week 0, week 16
Changes in fundoscopy/fundus photography from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Haematocrit
時間枠：Week 0, week 16
Changes in haematology - haematocrit from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Haemoglobin
時間枠：Week 0, week 16
Changes in haematology - haemoglobin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Leukocytes
時間枠：Week 0, week 16
Changes in haematology - leukocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Thrombocytes
時間枠：Week 0, week 16
Changes in haematology - thrombocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Haematology - Erythrocytes
時間枠：Week 0, week 16
Changes in haematology - erythrocytes from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Alanine Aminotransferase (ALT)
時間枠：Week 0, week 16
Changes in biochemistry - alanine aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Alkaline Phosphatase
時間枠：Week 0, week 16
Changes in biochemistry - alkaline phosphatase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Aspartate Aminotransferase (AST)
時間枠：Week 0, week 16
Changes in biochemistry - aspratate aminotransferase from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Albumin
時間枠：Week 0, week 16
Changes in biochemistry - albumin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Creatinine
時間枠：Week 0, week 16
Changes in biochemistry - creatinine from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Potassium
時間枠：Week 0, week 16
Changes in biochemistry - potassium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Sodium
時間枠：Week 0, week 16
Changes in biochemistry - sodium from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Total Bilirubin
時間枠：Week 0, week 16
Changes in biochemistry - total bilirubin from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Biochemistry - Total Protein
時間枠：Week 0, week 16
Changes in biochemistry - total protein from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Body Weight
時間枠：Week 0, week 16
Changes in body weight from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16
Change From Baseline in Body Mass Index (BMI)
時間枠：Week 0, week 16
Change in the body mass index (BMI) from baseline (week 0) were evaluated after 16 weeks of randomisation. The results are based on the last on-treatment value, which included the last available measurement in the on-treatment period. On-treatment period started from date of first dose of randomised NovoRapid/faster aspart and to 7 days after day of last dose or day before initiation of ancillary treatment.
Week 0, week 16

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

スポンサー

研究を開始し、研究に対する権限と管理権を持つ組織または個人。
Novo Nordisk A/S

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

研究開始

最初の参加者が臨床試験に登録された実際の日付。 「予想される」研究開始日は、研究者が研究開始日になると考える日付です。
2017年9月19日

一次修了 (実際)

一次修了

臨床研究の最後の参加者が検査された、または主要な結果測定のための最終データを収集するための介入を受けた日付。治験がプロトコルに従って終了したか終了したかは、この日付には影響しません。完了日が異なる複数の主要評価項目を含む臨床研究の場合、この用語は、すべての主要評価項目のデータ収集が完了した日付を指します。 「予想される」一次完了日は、研究者がその研究の一次完了日になると考える日付です。
2019年1月7日

研究の完了 (実際)

研究の完了

臨床研究の最後の参加者が検査された、または介入/治療を受けて、主要な結果の尺度、副次的な結果の尺度、および有害事象の最終データを収集した日付 (つまり、最後の参加者の最後の訪問)。 「予想される」研究完了日は、研究者が研究完了日になると考える日付です。
2019年1月29日

試験登録日

最初に提出

最初に提出

治験依頼者または治験責任医師が初めて治験記録を ClinicalTrials.gov に提出した日付。通常、最初の提出日と ClinicalTrials.gov での記録の利用可能日 (最初の投稿日) の間には数日の遅延があります。
2017年8月29日

QC基準を満たした最初の提出物

QC基準を満たした最初の提出物

研究スポンサーまたは治験責任医師が、国立医学図書館 (NLM) の品質管理 (QC) 審査基準と一致する研究記録を最初に提出した日付。治験依頼者または研究者は、NLM の QC 審査基準が満たされるまでに、研究記録を 1 回または複数回修正して提出する必要がある場合があります。研究記録がNLM QC審査基準と一致していることを確認するのは、治験依頼者または治験責任医師の責任です。
2017年8月29日

最初の投稿 (実際)

最初の投稿

国立医学図書館 (NLM) の品質管理 (QC) レビューが終了した後、ClinicalTrials.gov で研究記録が最初に利用可能になった日付。通常、治験依頼者または治験責任医師が治験記録を提出した日と最初に投稿された日との間には数日の遅延があります。
2017年8月31日

学習記録の更新

投稿された最後の更新 (実際)

投稿された最後の更新

ClinicalTrials.gov で、研究記録が変更された最新の日付。研究のスポンサーまたは治験責任医師によって変更が ClinicalTrials.gov に提出されたとき (最終更新が提出された日) と最終更新が投稿された日との間に遅延が生じる場合があります。
2022年1月11日

QC基準を満たした最後の更新が送信されました

QC基準を満たした最後の更新が送信されました

治験依頼者または治験責任医師が、国立医学図書館（NLM）の品質管理（QC）審査基準と一致する治験記録の変更を提出した最新の日付。研究記録がNLM QC審査基準と一致していることを確認するのは、治験依頼者または治験責任医師の責任です。
2022年1月6日

最終確認日

最終確認日

治験依頼者または治験責任医師が、ClinicalTrials.gov で臨床治験に関する情報が正確かつ最新であることを確認した最新の日付。募集ステータスが募集中の研究の場合。まだ募集していません。過去 2 年以内に募集が確認されていない場合、研究の募集状況は不明として表示されます。
2022年1月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

その他の研究ID番号

NCT 番号以外の識別子または ID 番号で、治験依頼者、資金提供者、その他によって臨床治験に割り当てられたもの。これらの番号には、他の治験登録機関や国立衛生研究所の助成金番号からの一意の識別子が含まれる場合があります。
  • NN1218-4113
  • U1111-1180-0636 (その他の識別子：World Health Organization (WHO))
  • 2016-000878-38 (レジストリ識別子：European Medicines Agency (EudraCT))

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

2型糖尿病の臨床試験

Faster-acting insulin aspartの臨床試験

類似の治験を検索

スポンサーと協力者

医学的状態

薬物療法

条件

まれな病気

薬物療法

ダイエットサプリメント

スポンサー/協力者

場所

クッキーの設定

当社はCookieを使用して、当社のWebサイトで最高のエクスペリエンスを提供できるようにしています。詳細については、プライバシーとCookieのポリシーをよくお読みください。...>>>ポリシーに記載されているように、WebサイトまたはコンピューターからCookieを削除することにより、いつでも設定を変更したり、同意を取り消すことができます。それを受け入れて、下の[設定の管理]セクションで対応するボックスにチェックマークを付けて、設定を選択してください。このウェブサイトの一部を使用する前に、利用規約をよくお読みください。
«設定の管理